These authors were, like us, concerned about the risk of local anesthetics when applied to living cells. They note that commonly used drugs lidocaine, ropivacaine, and bupivacaine can be toxic to human chondrocytes causing chondrolysis. This study seeks to determine whether the toxic effects of local anesthetics extends to human mesenchymal stem cells.
Human mesenchymal stem cells from three healthy donors were grown in tissue culture and exposed to the following anesthetic treatments for sixty minutes: (1) 1% lidocaine, (2) 2% lidocaine, (3) 0.25% bupivacaine, (4) 0.5% bupivacaine, (5) 0.2% ropivacaine, and (6) 0.5% ropivacaine. The cells were then allowed to recover for twenty-four hours in regular growth media, and viability was measured with use of fluorescent staining for live cells or a luminescence assay for ATP content.
They found that 2% lidocaine was significantly more toxic than all doses of bupivacaine and ropivacaine.
Ropivacaine and bupivacaine had limited toxicity in this model. However, lidocaine significantly decreased mesenchymal stem cell viability.
Mesenchymal stem cells may play a key role in healing following surgical procedures such as microfracture and ligament reconstruction. If local anesthetics are used following joint surgery, caution should be taken to avoid compromising tissue healing potential.
---
Use the "Search" box to the right to find other topics of interest to you.
You may be interested in some of our most visited web pages including:shoulder arthritis, total shoulder, ream and run, reverse total shoulder, CTA arthroplasty, and rotator cuff surgery.
See from which cities our patients come.
See the countries from which our readers come on this post.
Use the "Search" box to the right to find other topics of interest to you.
You may be interested in some of our most visited web pages including:shoulder arthritis, total shoulder, ream and run, reverse total shoulder, CTA arthroplasty, and rotator cuff surgery.
See from which cities our patients come.
See the countries from which our readers come on this post.
